Tumour relapse, chemotherapy resistance, and metastasis continue to be unsolved issues in cancer therapy. A recent approach has been to scrutinise drugs used in the clinic for other illnesses and modify their structure to increase selectivity to cancer cells. Chloroquine (CQ) and hydroxychloroquine (HCQ), known antimalarials, have successfully treated autoimmune and neoplastic diseases. CQ and HCQ, well-known lysosomotropic agents, induce apoptosis, downregulate autophagy, and modify the tumour microenvironment. Moreover, they affect the Toll 9/NF-κB receptor pathway, activate stress response pathways, enhance p53 activity and CXCR4-CXCL12 expression in cancer cells, which would help explain their effects in cancer treatment. These compounds can normalise the tumourassociated vasculature, promote the activation of the immune system, change the phenotype of tumour-associated macrophages (from M2 to M1), and stimulate cancer-associated fibroblasts. We aim to review the historical aspects of CQ and its derivatives and the most relevant mechanisms that support the therapeutic use of CQ and HCQ for the treatment of cancer.

Biotechnology Unit Faculty of Pharmacy Central University of Venezuela Los Chaguaramos 1041 A Caracas 47206 Venezuela

Faculty of Health Sciences and Human Development Research Directorate Center for Sustainable Development Studies ECOTEC University Samborondón Guayas Guayaquil 092302 Ecuador

Faculty of Medicine and Dentistry Institute of Molecular and Translational Medicine Palacky University Hněvotínská 1333 5 Olomouc 779 00 Czech Republic

Faculty of Medicine Institute of Immunology Central University of Venezuela Los Chaguaramos 1050 A Caracas 50109 Venezuela

Organic Synthesis Laboratory Faculty of Pharmacy Central University of Venezuela 47206 Los Chaguaramos 1041 A Caracas Venezuela

Citace poskytuje Crossref.org